Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
Open accessAbstract
RNA-guided endonucleases (RGENs) derived from the CRISPR/Cas system represent an efficient tool for genome editing. RGENs consist of two components: Cas9 protein and guide RNA. Plasmid-mediated delivery of these components into cells can result in uncontrolled integration of the plasmid sequence into the host genome, and unwanted immune responses and potential safety problems that can be caused by the bacterial sequences. Furthermore, this delivery method requires transfection tools. Here we show that simple treatment with cell-penetrating peptide (CPP)-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs leads to endogenous gene disruptions in human cell lines. The Cas9 protein was conjugated to CPP via a thioether bond, whereas the guide RNA was complexed with CPP, forming condensed, positively charged nanoparticles. Simultaneous and sequential treatment of human cells, including embryonic stem cells, dermal fibroblasts, HEK293T cells, HeLa cells, and embryonic carcinoma cells, with the modified Cas9 and guide RNA, leads to efficient gene disruptions with reduced off-target mutations relative to plasmid transfections, resulting in the generation of clones containing RGEN-induced mutations. Our CPP-mediated RGEN delivery process provides a plasmid-free and additional transfection reagent-free method to use this tool with reduced off-target effects. We envision that our method will facilitate RGEN-directed genome editing.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
RNP electroporation exhibits higher on-target editing efficiency and lower off-target mutations than other delivery methods.
“RNP electroporation exhibits higher on-target editing efficiency and lower off-target mutations than the other delivery methods”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Ramakrishna et al., 2014
The Results section studies cell-penetrating peptide (CPP) delivery, not RNP electroporation. It reports lower off-target mutation frequencies than plasmid delivery, but comparable on-target frequencies; another comparison found frequencies similar or slightly lower with CPP delivery. That contradicts the claimed higher on-target efficiency, and the paper does not establish the claim for electroporation or for other delivery methods generally. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredConjugating Cas9 and sgRNA with cell-penetrating peptides enhanced intracellular delivery efficiency because of the membrane-disturbed properties of CPPs.
“Ramakrishna et al. demonstrated that conjugating Cas9 and sgRNA with cell-penetrating peptides (CPPs) enhanced intracellular delivery efficiency because of the membrane-disturbed properties of CPPs.[227]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [227]
Ramakrishna et al. developed CPP-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs for gene disruptions of CCR5 locus in human cell lines, leading to efficient disruptions of CCR5 gene with minimal off-target mutations.
“Ramakrishna et al. developed cell-penetrating peptide (CPP)-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs for gene disruptions of CCR5 locus in human cell lines, including HEK293T, HeLa, NCCIT (a human pluripotent embryonal carcinoma cell line), human dermal fibroblasts and human embryonic stem cells.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [96]
Cell-penetrating peptide-mediated delivery of Cas9 and sgRNAs achieves a higher on-to-off-target activity ratio than plasmid-mediated delivery.
“Cell-penetrate-peptide-mediated delivery was reported to achieve higher on-to off-target activity ratio compared with plasmid-mediated delivery.53”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · see citing works
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339 · see citing works
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210 · see citing works
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · see citing works
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741 · see citing works
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495 · see citing works
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299 · see citing works
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · see citing works
Efficient genome editing in zebrafish using a CRISPR-Cas system
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937 · see citing works
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,471 · see citing works
RNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429 · see citing works
RNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098 · see citing works
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 3× · see citing works
“off-target effects using sgRNAs that do have reported off-target activities (Cho et al. 2014; Fu et al. 2014).”
BackgroundTargeted genome modification of crop plants using a CRISPR-Cas system
Shan, Q., Wang, Y., Li, J., Zhang, Y., Chen, K., Liang, Z., Zhang, K., Liu, J., Xi, J., Qiu, J., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2650 · Cited by 1,965 · see citing works
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863 · see citing works
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856 · see citing works
Self-citationRNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851 · see citing works
Yang, H., Wang, H., Shivalila, C. S., Cheng, A. W., Shi, L., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.022 · Cited by 1,596 · see citing works
Li, J., Norville, J. E., Aach, J., McCormack, M., Zhang, D., Bush, J., Church, G. M., & Sheen, J. (2013) · Nature Biotechnology · doi:10.1038/nbt.2654 · Cited by 1,499 · see citing works
Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487 · cited 1× · see citing works
“…effect) and specificity (off-target effect) are strongly affected by Cas9 protein and guide RNA concentrations (Fu et al. 2013; Hsu et al. 2013; Pattanayak et al. 2013), and (2) it is challenging to exactly control these concentrations so that they are the same in the CPP-mediated direct…”
BackgroundAnalysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases
Cho, S. W., Kim, S., Kim, Y., Kweon, J., Kim, H. S., Bae, S., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.162339.113 · Cited by 1,356 · see citing works
Self-citationTargeted mutagenesis in the model plant Nicotiana benthamiana using Cas9 RNA-guided endonuclease
Nekrasov, V., Staskawicz, B. J., Weigel, D., Jones, J. D. G., & Kamoun, S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2655 · Cited by 1,123 · see citing works
Genome Engineering of Drosophila with the CRISPR RNA-Guided Cas9 Nuclease
Gratz, S. J., Cummings, A. M., Nguyen, J. N., Hamm, D. C., Donohue, L. K., Harrison, M. M., Wildonger, J., & O’Connor-Giles, K. M. (2013) · Genetics · doi:10.1534/genetics.113.152710 · Cited by 959 · see citing works
Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination
Dickinson, D. J., Ward, J. D., Reiner, D. J., & Goldstein, B. (2013) · Nature Methods · doi:10.1038/nmeth.2641 · Cited by 915 · see citing works
Heritable genome editing in C. elegans via a CRISPR-Cas9 system
Friedland, A. E., Tzur, Y. B., Esvelt, K. M., Colaiácovo, M. P., Church, G. M., & Calarco, J. A. (2013) · Nature Methods · doi:10.1038/nmeth.2532 · Cited by 899 · see citing works
Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects
Shen, B., Zhang, W., Zhang, J., Zhou, J., Wang, J.-Y., Chen, L., Wang, L., Hodgkins, A., Iyer, V., Huang, X., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2857 · Cited by 827 · see citing works
Heritable gene targeting in the mouse and rat using a CRISPR-Cas system
Li, D., Qiu, Z., Shao, Y., Chen, Y., Guan, Y., Liu, M., Li, Y., Wang, L., Wang, L., Lu, X., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2661 · Cited by 639 · see citing works
A Rapid and General Assay for Monitoring Endogenous Gene Modification
Guschin, D. Y., Waite, A. J., Katibah, G. E., Miller, J. C., Holmes, M. C., & Rebar, E. J. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-753-2_15 · Cited by 500 · see citing works
Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly
Kim, H. J., Lee, H. J., Kim, H., Cho, S. W., & Kim, J.-S. (2009) · Genome Research · doi:10.1101/gr.089417.108 · Cited by 466 · see citing works
Self-citationLi, W., Teng, F., Li, T., & Zhou, Q. (2013) · Nature Biotechnology · doi:10.1038/nbt.2652 · Cited by 422 · see citing works
Targeted gene knockout by direct delivery of zinc-finger nuclease proteins
Gaj, T., Guo, J., Kato, Y., Sirk, S. J., & Barbas, C. F. (2012) · Nature Methods · doi:10.1038/nmeth.2030 · Cited by 306 · see citing works
Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleasesPreprint
Sung, Y. H., Kim, J. M., Kim, H.-T., Lee, J., Jeon, J., Jin, Y., Choi, J.-H., Ban, Y. H., Ha, S., Kim, C., et al. (2013) · Genome Research · doi:10.1101/gr.163394.113 · Cited by 281 · see citing works
Self-citationCho, S. W., Lee, J., Carroll, D., Kim, J., & Lee, J. (2013) · Genetics · doi:10.1534/genetics.113.155853 · Cited by 248 · see citing works
Surrogate reporters for enrichment of cells with nuclease-induced mutations
Kim, H., Um, E., Cho, S., Jung, C., Kim, J., & Kim, J. (2011) · Nature Methods · doi:10.1038/nmeth.1733 · Cited by 208 · see citing works
Self-citationWagner, H. (2001) · Immunity · doi:10.1016/s1074-7613(01)00144-3 · Cited by 181 · see citing works
Ding, H., Inoue, S., Ljubimov, A. V., Patil, R., Portilla‐Arias, J., Hu, J., Konda, B. M., Wawrowsky, K., Fujita, M., Karabalin, N., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003919107 · Cited by 167 · see citing works
Liu, J., Gaj, T., Patterson, J. T., Sirk, S. J., & Barbas, C. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085755 · Cited by 147 · see citing works
Surrogate reporter-based enrichment of cells containing RNA-guided Cas9 nuclease-induced mutations
Ramakrishna, S., Cho, S. W., Kim, S., Song, M., Gopalappa, R., Kim, J., & Kim, S. (2014) · Nature Communications · doi:10.1038/ncomms4378 · Cited by 134 · see citing works
Self-citationProcessing of DNA for nonhomologous end‐joining by cell‐free extract
Budman, J., & Chu, G. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600563 · Cited by 121 · see citing works
Cell-penetrating peptides (CPPs) as a vector for the delivery of siRNAs into cells
Nakase, I., Tanaka, G., & Futaki, S. (2012) · Molecular BioSystems · doi:10.1039/c2mb25467k · Cited by 111 · see citing works
Therapeutic Potential of cell-penetrating Peptides
Vasconcelos, D., Pärn, K., & Langel, Ü. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.22 · Cited by 90 · see citing works
Matsui, H., Tomizawa, K., Lü, Y.-F., & Matsushita, M. (2003) · Current Protein and Peptide Science · doi:10.2174/1389203033487270 · Cited by 71 · see citing works
Kim, H., Kim, M., Wee, G., Lee, C.-I., Kim, S., & Kim, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056476 · Cited by 61 · see citing works
Self-citationCell-penetrating peptides from cell cultures to in vivo applications
Regberg, J. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e632 · Cited by 25 · see citing works
Stability of Zinc Finger Nuclease Protein Is Enhanced by the Proteasome Inhibitor MG132
Ramakrishna, S., Kim, Y.-H., & Kim, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054282 · Cited by 23 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · see citing works
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,026 · see citing works
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856 · see citing works
Self-citationLi, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,771 · see citing works
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · see citing works
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S., & Yang, S.-H. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.37 · Cited by 1,273 · see citing works
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185 · see citing works
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N. X., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,201 · see citing works
CRISPR/Cas9 in Genome Editing and Beyond
Wang, H., Russa, M. F. L., & Qi, L. S. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014607 · Cited by 1,165 · see citing works
CRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,058 · see citing works
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2016) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,011 · see citing works
Digenome-seq: Genome-wide profiling of CRISPR-cas9 off-target effects in human cells
Kim, D., Bae, S., Park, J., Kim, E., Kim, S., Yu, H. R., Hwang, J., Kim, J.-I., & Kim, J.-S. (2015) · Nature Methods · doi:10.1038/nmeth.3284 · Cited by 992 · see citing works
Zhang, Y., Liang, Z., Zong, Y., Wang, Y., Liu, J., Chen, K., Qiu, J., & Gao, C. (2016) · Nature Communications · doi:10.1038/ncomms12617 · Cited by 906 · see citing works
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782 · see citing works
Lee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0137-2 · Cited by 755 · see citing works
Self-citationIntracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 748 · see citing works
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 770 · see citing works
Genome-editing Technologies for Gene and Cell Therapy
Maeder, M. L., & Gersbach, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.10 · Cited by 722 · see citing works
Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles
Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624 · see citing works
Self‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629 · see citing works
Off-target effects in CRISPR/Cas9 gene editing
Guo, C., Ma, X., Gao, F., & Guo, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1143157 · Cited by 625 · see citing works
“RNP electroporation exhibits higher on-target editing efficiency and lower off-target mutations than the other delivery methods (Kim et al., 2014; Ramakrishna et al., 2014).”
BackgroundPhotoactivatable CRISPR-Cas9 for optogenetic genome editing
Nihongaki, Y., Kawano, F., Nakajima, T., & Sato, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3245 · Cited by 609 · see citing works
Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
Liu, C., Zhang, L., Liu, H., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.012 · Cited by 607 · see citing works
Delivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597 · see citing works
Wei, T., Cheng, Q., Min, Y.-L., Olson, E. N., & Siegwart, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17029-3 · Cited by 603 · see citing works
Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing
Mout, R., Ray, M., Yesilbag Tonga, G., Lee, Y.-W., Tay, T., Sasaki, K., & Rotello, V. M. (2017) · ACS Nano · doi:10.1021/acsnano.6b07600 · Cited by 579 · see citing works
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560 · see citing works
Self-citationA highly specific SpCas9 variant is identified by in vivo screening in yeast
Casini, A., Olivieri, M., Petris, G., Montagna, C., Reginato, G., Maule, G., Lorenzin, F., Prandi, D., Romanel, A., Demichelis, F., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4066 · Cited by 493 · see citing works
CRISPR-Cas: biology, mechanisms and relevance
Hille, F., & Charpentier, E. (2016) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2015.0496 · Cited by 503 · see citing works
Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Communications · doi:10.1038/ncomms7244 · Cited by 470 · see citing works
DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing
Xue, C., & Greene, E. C. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.02.008 · Cited by 431 · see citing works
Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
Zhang, S., Shen, J., Li, D., & Cheng, Y. (2021) · Theranostics · doi:10.7150/thno.47007 · Cited by 430 · see citing works
Small molecule–triggered Cas9 protein with improved genome-editing specificity
Davis, K. M., Pattanayak, V., Thompson, D. B., Zuris, J. A., & Liu, D. R. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1793 · Cited by 418 · see citing works
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415 · see citing works
In vivo high-throughput profiling of CRISPR-Cpf1 activity
Kim, H. K., Song, M., Lee, J., Menon, A. V., Jung, S., Kang, Y.-M., Choi, J. W., Woo, E., Koh, H. C., Nam, J.-W., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4104 · Cited by 383 · see citing works
Self-citationTarget specificity of the CRISPR‐Cas9 system
Wu, X., Kriz, A. J., & Sharp, P. A. (2014) · Quantitative Biology · doi:10.1007/s40484-014-0030-x · Cited by 373 · see citing works
Gangoso, E., Southgate, B., Bradley, L., Lehr, S., Gálvez‐Cancino, F., McGivern, N., Güç, E., Kapourani, C.-A., Byron, A., Ferguson, K. M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.023 · Cited by 356 · see citing works
Staahl, B. T., Benekareddy, M., Coulon-Bainier, C., Banfal, A. A., Floor, S. N., Sabo, J. K., Urnes, C., Munares, G. A., Ghosh, A., & Doudna, J. A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3806 · Cited by 355 · see citing works
Engineering the delivery system for CRISPR-based genome editing
Glass, Z., Lee, M., Li, Y., & Xu, Q. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.11.006 · Cited by 345 · see citing works
Efficient Intracellular Delivery of Native Proteins
D’Astolfo, D. S., Pagliero, R. J., Pras, A., Karthaus, W. R., Clevers, H. C., Prasad, V., Lebbink, R. J., Rehmann, H., & Geijsen, N. (2015) · Cell · doi:10.1016/j.cell.2015.03.028 · Cited by 343 · see citing works
CRISPR/Cas9 Based Genome Editing of Penicillium chrysogenum
Pohl, C., Kiel, J. A. K. W., Driessen, A. J. M., Bovenberg, R. A. L., & Nygård, Y. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.6b00082 · Cited by 345 · see citing works
CRISPR-Cas9 system: A new-fangled dawn in gene editing
Gupta, D., Bhattacharjee, O., Mandal, D., Sen, M. K., Dey, D., Dasgupta, A., Kazi, T. A., Gupta, R. K., Sinharoy, S., Acharya, K., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116636 · Cited by 332 · see citing works
A Mouse Geneticist’s Practical Guide to CRISPR Applications
Singh, P., Schimenti, J. C., & Bolcun‐Filas, E. (2014) · Genetics · doi:10.1534/genetics.114.169771 · Cited by 303 · see citing works
Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing
Wilbie, D., Walther, J., & Mastrobattista, E. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00106 · Cited by 300 · see citing works
Recent Advances in CRISPR/Cas9 Delivery Strategies
Yip, B. H. (2020) · Biomolecules · doi:10.3390/biom10060839 · Cited by 303 · see citing works
Chen, Z., Liu, F., Chen, Y., Liu, J., Wang, X., Chen, A. T., Deng, G., Zhang, H., Liu, J., Hong, Z., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703036 · Cited by 297 · see citing works
Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice
Aida, T., Chiyo, K., Usami, T., Ishikubo, H., Imahashi, R., Wada, Y., Tanaka, K. F., Sakuma, T., Yamamoto, T., & Tanaka, K. (2015) · Genome biology · doi:10.1186/s13059-015-0653-x · Cited by 296 · see citing works
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 295 · see citing works
The delivery challenge: fulfilling the promise of therapeutic genome editing
van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N., & Schaffer, D. V. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0565-5 · Cited by 285 · see citing works
Wang, H.-X., Song, Z., Lao, Y.-H., Xu, X., Gong, J., Cheng, D., Chakraborty, S., Park, J. S., Li, M., Huang, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712963115 · Cited by 277 · see citing works
The CRISPR/Cas Genome-Editing Tool: Application in Improvement of Crops
Khatodia, S., Bhatotia, K., Passricha, N., Khurana, S. M. P., & Tuteja, N. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00506 · Cited by 267 · see citing works
Cell-penetrating peptides transport therapeutics into cells
Ramsey, J. D., & Flynn, N. H. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.003 · Cited by 255 · see citing works
Potential pitfalls of CRISPR /Cas9‐mediated genome editing
Peng, R., Lin, G., & Li, J. (2015) · FEBS Journal · doi:10.1111/febs.13586 · Cited by 248 · see citing works
In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges
Mout, R., Ray, M., Lee, Y.-W., Scaletti, F., & Rotello, V. M. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00057 · Cited by 247 · see citing works
Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice
Li, L., Song, L., Liu, X., Yang, X., Li, X., He, T., Wang, N., Yang, S., Yu, C., Yin, T., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b04261 · Cited by 244 · see citing works
In vivo gene delivery mediated by non-viral vectors for cancer therapy
Mohammadinejad, R., Dehshahri, A., Madamsetty, V. S., Zahmatkeshan, M., Tavakol, S., Makvandi, P., Khorsandi, D., Pardakhty, A., Ashrafizadeh, M., Afshar, E. G., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.038 · Cited by 238 · see citing works
CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation
Han, X., Liu, Z., Jo, M. C., Zhang, K., Li, Y., Zeng, Z., Li, N., Zu, Y., & Qin, L. (2015) · Science Advances · doi:10.1126/sciadv.1500454 · Cited by 232 · see citing works
CRISPR RNAs Trigger Innate Immune Responses in Human Cells
Kim, S., Koo, T., Jee, H.-G., Cho, H.-Y., Lee, G., Lim, D.-G., Shin, H. S., & Kim, J.-S. (2018) · Genome Research · doi:10.1101/gr.231936.117 · Cited by 222 · see citing works
Li, C., Guan, X., Du, T., Jin, W., Wu, B., Liu, Y., Wang, P., Hu, B., Griffin, G. E., Shattock, R. J., et al. (2015) · Journal of General Virology · doi:10.1099/vir.0.000139 · Cited by 220 · see citing works
Transgenic Mouse Models in Cancer Research
Tratar, U. L., Horvat, S., & Čemažar, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00268 · Cited by 216 · see citing works
Wang, P., Zhang, L., Xie, Y., Wang, N., Tang, R., Zheng, W., & Jiang, X. (2017) · Advanced Science · doi:10.1002/advs.201700175 · Cited by 213 · see citing works
Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy
Song, X., Liu, C., Wang, N., Huang, H., He, S., Gong, C., & Wei, Y. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.010 · Cited by 214 · see citing works
Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering
Hamilton, J. R., Tsuchida, C. A., Nguyen, D. N., Shy, B. R., McGarrigle, E. R., Espinoza, C. R. S., Carr, D., Blaeschke, F., Marson, A., & Doudna, J. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109207 · Cited by 208 · see citing works
CRISPR-Cas9 ribonucleoprotein-mediated co-editing and counterselection in the rice blast fungus
Foster, A. J., Martín-Urdiroz, M., Xia, Y., Wright, S., Soanes, D. M., & Talbot, N. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-32702-w · Cited by 205 · see citing works
Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq
Kim, D., Kim, S., Kim, S., Park, J., & Kim, J.-S. (2016) · Genome Research · doi:10.1101/gr.199588.115 · Cited by 208 · see citing works
Self-citationSomatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia
Lim, J. S., Gopalappa, R., Kim, S. H., Ramakrishna, S., Lee, M., Kim, J., Kim, J., Park, S. M., Lee, J., Oh, J., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.01.030 · Cited by 208 · see citing works
Self-citationMeasuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9
Koo, T., Lee, J., & Kim, J. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0103 · Cited by 206 · see citing works
Challenges in CRISPR/CAS9 delivery: potential roles of nonviral vectors
Li, L., He, Z.-Y., Wei, X.-W., Gao, G.-P., & Wei, Y.-Q. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.069 · Cited by 202 · see citing works
Cell penetrating peptides: the potent multi-cargo intracellular carriers
Kardani, K., Milani, A., Shabani, S. H., & Bolhassani, A. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1676720 · Cited by 199 · see citing works
CRISPR-Cas9: a new and promising player in gene therapy
Xiao-Jie, L., Hui-Ying, X., Zun-Ping, K., Jin-Lian, C., & Li-Juan, J. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102968 · Cited by 200 · see citing works
A chemical-inducible CRISPR–Cas9 system for rapid control of genome editing
Liu, K. I., Ramli, M. N., Woo, A., Wang, Y., Zhao, T., Zhang, X., Yim, D., Chong, B. Y., Ali, G., Chua, M. Z. H., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2179 · Cited by 194 · see citing works
Prime editing: advances and therapeutic applications
Zhao, Z., Shang, P., Mohanraju, P., & Geijsen, N. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.03.004 · Cited by 199 · see citing works
Rational designs of in vivo CRISPR-Cas delivery systems
Xu, C., Chen, G., Luo, Y., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 185 · see citing works
Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX
Yu, X., Liang, X., Xie, H., Kumar, S., Ravinder, N., Potter, J., du Jeu, X. D. M., & Chesnut, J. D. (2016) · Biotechnology Letters · doi:10.1007/s10529-016-2064-9 · Cited by 174 · see citing works
Bak, R. O., Gomez‐Ospina, N., & Porteus, M. H. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.004 · Cited by 176 · see citing works
Evaluating and enhancing target specificity of gene-editing nucleases and deaminases
Kim, D., Luk, K., Wolfe, S. A., & Kim, J.-S. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111730 · Cited by 171 · see citing works
Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing
Rouet, R., Thuma, B. A., Roy, M. D., Lintner, N. G., Rubitski, D. M., Finley, J. E., Wisniewska, H. M., Mendonsa, R., Hirsh, A., de Oñate, L., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01551 · Cited by 163 · see citing works
CRISPR ribonucleoprotein-mediated genetic engineering in plants
Zhang, Y., Iaffaldano, B. J., & Qi, Y. (2021) · Plant Communications · doi:10.1016/j.xplc.2021.100168 · Cited by 169 · see citing works
CRISPR/Cas9-mediated genome editing and gene replacement in plants: Transitioning from lab to field
Schaeffer, S. M., & Nakata, P. A. (2015) · Plant Science · doi:10.1016/j.plantsci.2015.09.011 · Cited by 162 · see citing works
Cell Penetrating Peptides, Novel Vectors for Gene Therapy
Taylor, R. E., & Zahid, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030225 · Cited by 160 · see citing works
Cellular distribution of injected PLGA-nanoparticles in the liver
Park, J., Utsumi, T., Seo, Y.-E., Deng, Y., Satoh, A., Saltzman, W. M., & Iwakiri, Y. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.01.013 · Cited by 154 · see citing works
Han, X., Alu, A., Liu, H., Shi, Y., Wei, X., Cai, L., & Wei, Y. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.011 · Cited by 159 · see citing works
Genome-Edited Triple-Recessive Mutation Alters Seed Dormancy in Wheat
Abe, F., Haque, E., Hisano, H., Tanaka, T., Kamiya, Y., Mikami, M., Kawaura, K., Endo, M., Onishi, K., Hayashi, T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.090 · Cited by 151 · see citing works
Graphene oxide-mediated Cas9/sgRNA delivery for efficient genome editing
Yue, H., Zhou, X., Cheng, M., & Xing, D. (2018) · Nanoscale · doi:10.1039/c7nr07999k · Cited by 150 · see citing works
Genome-wide profiling of adenine base editor specificity by EndoV-seq
Liang, P., Xie, X., Zhi, S., Sun, H., Zhang, X., Chen, Y., Chen, Y., Xiong, Y., Ma, W., Liu, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07988-z · Cited by 148 · see citing works
Jacobi, A. M., Rettig, G. R., Turk, R., Collingwood, M. A., Zeiner, S. A., Quadros, R. M., Harms, D. W., Bonthuis, P. J., Gregg, C. J., Ohtsuka, M., et al. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.021 · Cited by 142 · see citing works
Immunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 146 · see citing works
Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, X., Wan, T. Y., Xin, H., Li, D., Pan, H., Wu, J., & Yuan, P. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3107 · Cited by 147 · see citing works
Applications and developments of gene therapy drug delivery systems for genetic diseases
Pan, X., Veroniaina, H., Su, N., Sha, K., Jiang, F., Wu, Z., & Qi, X. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.05.003 · Cited by 140 · see citing works
Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP
Lin, Y., Wagner, E., & Lächelt, U. (2022) · Biomaterials Science · doi:10.1039/d1bm01658j · Cited by 141 · see citing works
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 143 · see citing works
Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.029 · Cited by 137 · see citing works
Use of RNA-Protein Complexes for Genome Editing in Non- albicans Candida Species
Grahl, N., Demers, E. G., Crocker, A. W., & Hogan, D. A. (2017) · mSphere · doi:10.1128/msphere.00218-17 · Cited by 133 · see citing works
Genome editing at the crossroads of delivery, specificity, and fidelity
Maggio, I., & Gonçalves, M. A. F. V. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.02.011 · Cited by 132 · see citing works
Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos
Tu, Z., Yang, W., Yan, S., Yin, A., Gao, J., Liu, X., Zheng, Y., Zheng, J., Li, Z., Yang, S., et al. (2017) · Scientific Reports · doi:10.1038/srep42081 · Cited by 133 · see citing works
Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN
Ain, Q. U., Chung, J. Y., & Kim, Y.-H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.036 · Cited by 130 · see citing works
Self‐Assembled DNA Nanoclews for the Efficient Delivery of CRISPR–Cas9 for Genome Editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie · doi:10.1002/ange.201506030 · Cited by 131 · see citing works
Recent Advances in Genome Editing Using CRISPR/Cas9
Ding, Y., Li, H., Chen, L., & Xie, K. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00703 · Cited by 131 · see citing works
Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics
Givens, B. E., Naguib, Y. W., Geary, S. M., Devor, E. J., & Salem, A. K. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0267-9 · Cited by 132 · see citing works
Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells
Liu, J., Gaj, T., Yang, Y., Wang, N., Shui, S., Kim, S., Kanchiswamy, C. N., Kim, J., & Barbas, C. F. (2015) · Nature Protocols · doi:10.1038/nprot.2015.117 · Cited by 127 · see citing works
- Authors
- Ramakrishna, S., Kwaku Dad, A.-B., Beloor, J., Gopalappa, R., Lee, S.-K., & Kim, H.
- Affiliations
- Hanyang University (KR)
- Venue
- Genome Research
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-04-02
- Volume
- 24
- Issue
- 6
- Pages
- 1020-1027
- ISSN
- 1088-9051 (ISSN-L)
- PMC
- PMC4032848
- OpenAlex
- W2103609218
- Cited by
- 655
- References
- 45
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 41 · 2023: 46 · 2022: 64 · 2021: 76 · 2020: 66 · 2019: 60 · 2018: 77 · 2017: 60 · 2016: 56 · 2015: 50 · 2014: 11 · 2013: 1
- Type
- posted content
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Genome Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Research Foundation
- Hanyang University
- Yonsei University
- Korea Basic Science Institute
- National Research Foundation of Korea (2013M3A9B4076544, 2011‐0019357)
- Korea Advanced Institute of Science and Technology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- CRISPR/Cas9, cell-penetrating peptides, gene disruption, genome editing, guide RNA delivery, off-target mutations, embryonic stem cells, human cell lines
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Humans, Transfection, Genome, Human, Mutagenesis, Site-Directed, RNA Editing, RNA, Guide, Kinetoplastida, Cell Line, Tumor, Nanoparticles, HEK293 Cells, Cell-Penetrating Peptides, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
